Brolucizumab-early experience with early extended interval regime in chronic centre involved diabetic macular oedema

Eye (Lond). 2022 Feb;36(2):358-360. doi: 10.1038/s41433-021-01816-3. Epub 2021 Oct 13.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Diabetes Mellitus*
  • Diabetic Retinopathy* / complications
  • Diabetic Retinopathy* / drug therapy
  • Humans
  • Macular Edema* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • brolucizumab